-
Bestatin (Ubenimex) in Aminopeptidase Workflows
2026-08-14
Bestatin (Ubenimex) connects enzyme-selective aminopeptidase inhibition with practical cell-based studies of apoptosis, multidrug resistance, and cancer biology. This guide shows how to move from activity measurement to phenotype while controlling solubility, exposure, assay specificity, and interpretation.
-
VER 155008: HSP 70 Inhibitor Workflows
2026-08-13
VER 155008 connects biochemical measurement of Hsp70 ATPase activity with cell-based studies of apoptosis and cancer cell proliferation inhibition. This guide shows how to control solvent effects, separate cytostasis from cell death, and extend chaperone biology into a carefully bounded TDP-43 condensate model.
-
HyperScript™ RT SuperMix for qPCR: 5 Lab Scenarios
2026-08-13
This scenario-driven guide explains how HyperScript™ RT SuperMix for qPCR, SKU K1074, can support reproducible cDNA synthesis for viability, proliferation, cytotoxicity, and cancer-stemness studies. It connects formulation features with practical decisions involving low-input RNA, complex templates, qRT-PCR controls, interpretation, and vendor selection.
-
X-press Tag Peptide in RHEB Signaling Research
2026-08-12
A translational perspective on using X-press Tag Peptide as an N-terminal leader peptide to connect recombinant protein purification, orthogonal detection, and mechanistic studies of the UBE2F–SAG–RHEB–mTORC1 axis.
-
3D Organoid–Fibroblast Models of PDAC Chemoresistance
2026-08-12
Schuth and colleagues developed a patient-specific three-dimensional co-culture system that combines pancreatic ductal adenocarcinoma organoids with matched cancer-associated fibroblasts. The model revealed increased tumor-cell proliferation, reduced chemotherapy-induced death, and stromal induction of inflammatory and epithelial-to-mesenchymal transition programs, showing why epithelial-only organoids can underestimate microenvironment-mediated drug resistance.
-
Targeted Amikacin Delivery into Mycobacterial Granulomas
2026-08-11
Montes-Worboys and colleagues developed a dendritic-cell delivery strategy to direct fluorescently labeled amikacin into Mycobacterium avium granulomas in infected mice. The study provides proof-of-concept for localized aminoglycoside delivery, while also showing that the modified drug retained comparable antimycobacterial activity and did not produce the measured inflammatory signal.
-
Cycloastragenol Protects Against GIONFH in Rats
2026-08-11
This in vivo study shows that cycloastragenol limits methylprednisolone-associated femoral-head damage in rats by suppressing osteoclast activity, preserving trabecular bone, and improving local blood supply. Its value is mechanistic as well as therapeutic: the findings position the RANKL/OPG axis and osteoclast-resorption program as measurable targets for hip-preservation research, while still requiring validation beyond the animal model.
-
TH287 Radiosensitizes Castration-Resistant Prostate Cancer
2026-08-10
The reference study shows that TH287 can enhance ionizing-radiation responses in PC-3 and DU-145 castration-resistant prostate cancer cells, with the strongest effect when radiation follows initial inhibitor exposure by 12 hours. Its main innovation is the treatment-schedule analysis, supported by survival, apoptosis, protein-expression, and cell-cycle measurements.
-
Sulfo-NHS-SS-Biotin for AML Surface Mapping
2026-08-09
Sulfo-NHS-SS-Biotin enables reversible surface-amine labeling that can complement emerging AML target-discovery workflows. This article explains how its cleavable chemistry can distinguish accessible cell-surface biology from intracellular abundance, using recent csNPM1 findings to guide assay design.
-
Pitavastatin (NK-104): In Vitro Workflow Guide
2026-08-08
Pitavastatin (NK-104) provides a practical way to inhibit HMG-CoA reductase and study cholesterol biosynthesis in cellular or biochemical assays. This dossier-based guide covers preparation, controls, QC, and interpretation limits; the compound is not validated here for clinical treatment or in vivo animal workflows.
-
Annexin V, human recombinant: Assay Guide
2026-08-07
Learn how Annexin V, human recombinant (SKU K2064) can strengthen apoptosis and cytotoxicity workflows by measuring phosphatidylserine externalization alongside metabolic or viability endpoints. This scenario-based guide covers assay design, calcium-dependent binding, interpretation, optimization, and practical reagent selection.
-
Dlin-MC3-DMA: Ionizable Cationic Liposome Transforming RNA D
2026-08-07
Dlin-MC3-DMA’s ionizable cationic liposome chemistry is redefining RNA therapeutics, delivering unmatched potency for both siRNA and mRNA workflows. Its integration with machine learning-driven LNP design is accelerating breakthroughs in gene silencing and immunomodulation, especially for challenging cell types like microglia.
-
GPR35-KLF5 Circuitry Regulates Epithelial Repair in DSS Coli
2026-08-06
This study uncovers a tryptophan metabolic gatekeeping mechanism in which GPR35 senses mucosal damage and activates KLF5-dependent programming for epithelial repair. The findings clarify how intestinal epithelial cells decode injury signals, offering mechanistic insight for advancing ulcerative colitis research using DSS-induced mouse models.
-
S Tag Peptide: Practical Use for Solubility and Detection
2026-08-06
S Tag Peptide addresses common recombinant protein workflow challenges by enhancing solubility and enabling antibody-based detection. It is best suited for applications requiring robust purification and detection, but is unsuitable where ethanol solubility or independent enzymatic activity is needed.
-
EPI-001: Androgen Receptor N-Terminal Domain Inhibitor Workf
2026-08-05
EPI-001 offers researchers a powerful tool to inhibit androgen receptor activity at the N-terminal domain, enabling targeted investigation of resistant prostate and triple-negative breast cancer models. This guide translates recent findings into actionable protocols, troubleshooting tactics, and advanced applications, driving more robust outcomes in AR-driven oncology research.